Literature DB >> 21592982

Varicella zoster virus DNA at inoculation sites and in saliva after Zostavax immunization.

Duane L Pierson1, Satish K Mehta, Don Gilden, Randall J Cohrs, Maria A Nagel, D Scott Schmid, Stephen K Tyring.   

Abstract

Analysis of 36 individuals over age 60 years who were immunized with Zostavax revealed varicella zoster virus (VZV) DNA in swabs of skin inoculation sites obtained immediately after immunization in 18 (50%) of 36 subjects (copy number per nanogram of total DNA, 28 to 2.1 × 10(6)) and in saliva collected over 28 days in 21 (58%) of 36 subjects (copy number, 20 to 248). Genotypic analysis of DNA extracted from 9 random saliva samples identified vaccine virus in all instances. In some immunized individuals over age 60, vaccine virus DNA is shed in saliva up to 4 weeks.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21592982      PMCID： PMC3096786          DOI： 10.1093/infdis/jir139

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  15 in total

1.  Reactivation of 2 genetically distinct varicella-zoster viruses in the same individual.

Authors:  Y Taha; F T Scott; S P Parker; D Syndercombe Court; M L Quinlivan; J Breuer
Journal:  Clin Infect Dis       Date:  2006-10-11       Impact factor: 9.079

2.  Herpes zoster in an adult recipient of live attenuated varicella vaccine.

Authors:  M R Hammerschlag; A A Gershon; S P Steinberg; L Clarke; L D Gelb
Journal:  J Infect Dis       Date:  1989-09       Impact factor: 5.226

3.  Rapid genotyping of varicella-zoster virus vaccine and wild-type strains with fluorophore-labeled hybridization probes.

Authors:  V N Loparev; K McCaustland; B P Holloway; P R Krause; M Takayama; D S Schmid
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

Review 4.  Varicella-zoster virus T cell tropism and the pathogenesis of skin infection.

Authors:  Ann M Arvin; Jennifer F Moffat; Marvin Sommer; Stefan Oliver; Xibing Che; Susan Vleck; Leigh Zerboni; Chia-Chi Ku
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

5.  A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.

Authors:  M N Oxman; M J Levin; G R Johnson; K E Schmader; S E Straus; L D Gelb; R D Arbeit; M S Simberkoff; A A Gershon; L E Davis; A Weinberg; K D Boardman; H M Williams; J Hongyuan Zhang; P N Peduzzi; C E Beisel; V A Morrison; J C Guatelli; P A Brooks; C A Kauffman; C T Pachucki; K M Neuzil; R F Betts; P F Wright; M R Griffin; P Brunell; N E Soto; A R Marques; S K Keay; R P Goodman; D J Cotton; J W Gnann; J Loutit; M Holodniy; W A Keitel; G E Crawford; S-S Yeh; Z Lobo; J F Toney; R N Greenberg; P M Keller; R Harbecke; A R Hayward; M R Irwin; T C Kyriakides; C Y Chan; I S F Chan; W W B Wang; P W Annunziato; J L Silber
Journal:  N Engl J Med       Date:  2005-06-02       Impact factor: 91.245

6.  DNA sequence variability in isolates recovered from patients with postvaccination rash or herpes zoster caused by Oka varicella vaccine.

Authors:  Vladimir N Loparev; Elena Rubtcova; Jane F Seward; Myron J Levin; D Scott Schmid
Journal:  J Infect Dis       Date:  2007-01-10       Impact factor: 5.226

7.  Extraction of cell-associated varicella-zoster virus DNA with triton X-100-NaCl.

Authors:  D H Gilden; Y Shtram; A Friedmann; M Wellish; M Devlin; A Cohen; N Fraser; Y Becker
Journal:  J Virol Methods       Date:  1982-05       Impact factor: 2.014

8.  Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995-2005.

Authors:  Sandra S Chaves; Penina Haber; Kimp Walton; Robert P Wise; Hector S Izurieta; D Scott Schmid; Jane F Seward
Journal:  J Infect Dis       Date:  2008-03-01       Impact factor: 5.226

9.  Transmission of a newly characterized strain of varicella-zoster virus from a patient with herpes zoster in a long-term-care facility, West Virginia, 2004.

Authors:  Adriana S Lopez; Andrea Burnett-Hartman; Ram Nambiar; Linda Ritz; Patricia Owens; Vladimir N Loparev; Dalya Guris; D Scott Schmid
Journal:  J Infect Dis       Date:  2008-03-01       Impact factor: 5.226

10.  Varicella-zoster virus in the saliva of patients with herpes zoster.

Authors:  Satish K Mehta; Stephen K Tyring; Donald H Gilden; Randall J Cohrs; Melanie J Leal; Victoria A Castro; Alan H Feiveson; C Mark Ott; Duane L Pierson
Journal:  J Infect Dis       Date:  2008-03-01       Impact factor: 5.226
View more
  10 in total

1.  The history and mystery of VZV in saliva.

Authors:  Anne A Gershon
Journal:  J Infect Dis       Date:  2011-09-15       Impact factor: 5.226

Review 2.  The emerging safety profile of JAK inhibitors in rheumatic disease.

Authors:  Kevin L Winthrop
Journal:  Nat Rev Rheumatol       Date:  2017-03-02       Impact factor: 20.543

3.  Search for varicella zoster virus DNA in saliva of healthy individuals aged 20-59 years.

Authors:  Marius Birlea; Randall J Cohrs; Nathan Bos; Satish K Mehta; Duane L Pierson; Don Gilden
Journal:  J Med Virol       Date:  2013-11-06       Impact factor: 2.327

4.  Persistence of varicella zoster virus DNA in saliva after herpes zoster.

Authors:  Maria A Nagel; Alexander Choe; Randall J Cohrs; Igor Traktinskiy; Kyle Sorensen; Satish K Mehta; Duane L Pierson; Stephen K Tyring; Kassie Haitz; Catherine Digiorgio; Whitney Lapolla; Don Gilden
Journal:  J Infect Dis       Date:  2011-09-15       Impact factor: 5.226

Review 5.  Varicella-zoster.

Authors:  Don Gilden; Maria A Nagel; Randall J Cohrs
Journal:  Handb Clin Neurol       Date:  2014

6.  Longitudinal study on oral shedding of herpes simplex virus 1 and varicella-zoster virus in individuals infected with HIV.

Authors:  Monique van Velzen; Werner J D Ouwendijk; Stacy Selke; Suzan D Pas; Freek B van Loenen; Albert D M E Osterhaus; Anna Wald; Georges M G M Verjans
Journal:  J Med Virol       Date:  2013-06-18       Impact factor: 2.327

7.  Varicella-Zoster Virus DNA in Blood After Administration of Herpes Zoster Vaccine.

Authors:  Myron J Levin; Guang-Yun Cai; Katherine S Lee; Nadine G Rouphael; Aneesh K Mehta; Jennifer Canniff; Mark J Mulligan; Adriana Weinberg
Journal:  J Infect Dis       Date:  2018-03-13       Impact factor: 7.759

8.  One-year follow-up of patients with long-lasting post-herpetic neuralgia.

Authors:  Francesca Pica; Antonio Gatti; Marco Divizia; Marzia Lazzari; Marco Ciotti; Alessandro Fabrizio Sabato; Antonio Volpi
Journal:  BMC Infect Dis       Date:  2014-11-01       Impact factor: 3.090

9.  The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial.

Authors:  Kevin L Winthrop; Ann G Wouters; Ernest H Choy; Koshika Soma; Jennifer A Hodge; Chudy I Nduaka; Pinaki Biswas; Elie Needle; Sherry Passador; Christopher F Mojcik; William F Rigby
Journal:  Arthritis Rheumatol       Date:  2017-09-06       Impact factor: 10.995

10.  Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies.

Authors:  Kim A Papp; Boulos Haraoui; Deepali Kumar; John K Marshall; Robert Bissonnette; Alain Bitton; Brian Bressler; Melinda Gooderham; Vincent Ho; Shahin Jamal; Janet E Pope; A Hillary Steinhart; Donald C Vinh; John Wade
Journal:  J Cutan Med Surg       Date:  2018-11-21       Impact factor: 2.092
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.